Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region

opinion statement from China, Japan, Taiwan, Korea, and Australia

Dingwei Ye*, Masatoshi Eto, Jin Soo Chung, Go Kimura, Wen Cheng Chang, Yen Hwa Chang, See Tong Pang, Jae Lyun Lee, Yuanjie Niu, Howard Gurney, Hirotsugu Uemura

*Corresponding author for this work

    Research output: Contribution to journalReview article

    16 Citations (Scopus)


    Rates of renal cell carcinoma (RCC) morbidity and mortality vary widely by geography, with increasing incidence in most countries. Interestingly, RCC incidence is significantly lower in Asian countries relative to other regions, which is attributed to environmental and genetic influences. Additionally, it has been demonstrated that different ethnic groups differ in their RCC characteristics which might lead to varied responses to therapy. In this review, physicians drawn from countries across the Asia-Pacific region - China, Japan, Taiwan, Republic of Korea, and Australia - take all available data into consideration to develop the first opinion statement on treatment of advanced RCC in the region. We have sought to determine what factors influence treatment patterns and availability of therapeutic agents in our respective countries, discussed whether these factors are fully justified or should be modified, and considered what additional efforts should be undertaken to optimize treatment outcomes in RCC. Additionally, we have addressed the limitations on treatment of RCC in the region, capturing the restrictive situations of targeted therapy use in the Asia-Pacific region, mainly because of drug availability and treatment reimbursement. Often this illustrates the gap between Western and regional or even among local guidelines, the opinions of leading physicians regarding the treatment, and the realistic access to agents for most patients. Proposals made in this document are based on clinical experience and data from clinical trials of RCC therapies in which Asian patients have been included.

    Original languageEnglish
    Pages (from-to)225-233
    Number of pages9
    JournalClinical Genitourinary Cancer
    Issue number4
    Publication statusPublished - Aug 2014

    Fingerprint Dive into the research topics of 'Use of targeted therapies for advanced renal cell carcinoma in the asia-pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia'. Together they form a unique fingerprint.

    Cite this